Download PDF
Planta Med 2023; 89(10): 990-1000
DOI: 10.1055/a-2014-6061
Biological and Pharmacological Activity
Original Papers

Network Pharmacology and Mechanism Studies of the Protective Effect of Ginseng against Alzheimerʼs Disease Based on Aβ Pathogenesis

Jinman Liu 
1   Affiliated Jiangmen TCM Hospital of Jiʼnan University, Jiangmen, China
,
Wenqian Yu
2   Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
,
Cuiru Ma
2   Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
,
Tianyao Li
2   Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
,
Yong Liang
2   Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
,
Shijie Su
2   Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
,
Guangcheng Zhong
2   Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
,
Zhouyuan Xie
2   Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
,
Qiqing Wu
2   Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
,
Jiaxin Chen
2   Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
,
Qi Wang
2   Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
› Author AffiliationsSupported by: Key laboratory project of colleges and universities in Guangdong province 2019KSYS005
Supported by: science and technology program of Guangzhou 202201011195
Supported by: National Natural Science Foundation of China 21904110
Supported by: National Natural Science Foundation of China 81973918
Supported by: Guangdong province science and technology plan international cooperation project 2020A0505100052
› Further Information
    Permissions and Reprints

Abstract

Alzheimerʼs disease (AD) is a critical neurodegenerative disease that manifests as progressive intellectual decline and is pathologically characterized by a progressive loss of neurons in the brain. Despite extensive research on this topic, the pathogenesis of AD is not fully understood, while the beta-amyloid (Aβ) hypothesis remains the dominant one and only a few symptomatic drugs are approved for the treatment of AD. Ginseng has been widely reported as an effective herbal medicine for the treatment of neurodegenerative diseases such as dementia. Therefore, we explore the protective effects of ginseng in AD by a network pharmacological approach based on the pathogenesis of Aβ. Twenty-one major ginsenosides are screened based on ultraperformance liquid chromatography-mass spectrometry/mass spectrometry (HPLC-MS/MS) data. Among them, MAPK8, MAPK9, BACE1, FLT1, CDK2, and CCR5 are the core targets. By molecular docking and validation with the in vitro cell model APPswe-SH-SY5Y, we find that ginsenosides Rg3 and Ro have good neuroprotective effects and can reduce the expression of Aβ 1 – 42 in APPswe-SH-SY5Y. Finally, through RT-qPCR experiment, we find that ginsenoside Rg3 targeted MAPK8, FLT1, and CCR5, while ginsenoside Ro targeted MAPK8, MAPK9, FLT1, and CCR5 for its potential anti-AD efficacy.

Key words

Ginseng - Araliaceae - Alzheimerʼs disease - beta-amyloid - network pharmacology - targets

Supporting Information

    Schematic diagram of molecular docking results of donepezil, dose-dependent experiments for copper to cause APPswe-SH-SY5Y cell injury and apoptosis model, the mean contents of ginsenosides and their standard deviation and standard error, major ginsenosides in ginseng and their properties, ranking of 60 genes targeting Aβ in ginsenosides by degree, enrichment analysis in DisGeNET, and primers used for real-time quantitative PCR are available as supporting information.

  • Supporting Information


Publication History

Received: 15 October 2022

Accepted after revision: 16 January 2023

Accepted Manuscript online:
17 January 2023

Article published online:
14 July 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mattson MP. Pathways towards and away from Alzheimerʼs disease. Nature 2004; 430: 631-639
    CrossrefPubMedGoogle Scholar
  • 2 Wimo A. Long-term effects of Alzheimerʼs disease treatment. Lancet Neurol 2015; 14: 1145-1146
    CrossrefPubMedGoogle Scholar
  • 3 Hinz FI, Geschwind DH. Molecular genetics of neurodegenerative dementias. Cold Spring Harb Perspect Biol 2017; 9: a023705
    CrossrefPubMedGoogle Scholar
  • 4 Paroni G, Bisceglia P, Seripa D. Understanding the amyloid hypothesis in Alzheimerʼs disease. J Alzheimers Dis 2019; 68: 493-510
    CrossrefPubMedGoogle Scholar
  • 5 Hung SY, Fu WM. Drug candidates in clinical trials for Alzheimerʼs disease. J Biomed Sci 2017; 24: 47
    CrossrefPubMedGoogle Scholar
  • 6 Mangialasche F, Solomon A, Winblad B, Mecocc P, Kivipelto M. Alzheimerʼs disease: Clinical trials and drug development. Lancet Neurol 2010; 9: 702-716:
    CrossrefPubMedGoogle Scholar
  • 7 Fillit H, Green A. Aducanumab and the FDA – where are we now?. Nat Rev Neurol 2021; 17: 129-130
    CrossrefPubMedGoogle Scholar
  • 8 Zhao B, Lv C, Lu J. Natural occurring polysaccharides from Panax ginseng C. A. Meyer: A review of isolation, structures, and bioactivities. Int J Biol Macromol 2019; 133: 324-336
    CrossrefPubMedGoogle Scholar
  • 9 Kim HJ, Jung SW, Kim SY, Cho IH, Kim HC, Rhim H, Kim M, Nah SY. Panax ginseng as an adjuvant treatment for Alzheimerʼs disease. J Ginseng Res 2018; 42: 401-411
    CrossrefPubMedGoogle Scholar
  • 10 Shin SJ, Jeon SG, Kim JI, Jeong YO, Kim S, Park YH, Lee SK, Park HH, Hong SB, Oh S, Hwang JY, Kim HS, Park H, Nam Y, Lee YY, Kim JJ, Park SH, Kim JS, Moon M. Red ginseng attenuates Aβ-induced mitochondrial dysfunction and Aβ-mediated pathology in an animal model of Alzheimerʼs disease. Int J Mol Sci 2019; 20: 3030
    CrossrefPubMedGoogle Scholar
  • 11 Ong WY, Farooqui T, Koh HL, Farooqui AA, Ling EA. Protective effects of ginseng on neurological disorders. Front Aging Neurosci 2015; 7: 129
    PubMedGoogle Scholar
  • 12 Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, Kim M. An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimerʼs disease. Eur J Neurol 2008; 15: 865-868
    CrossrefPubMedGoogle Scholar
  • 13 Nah SY. Ginseng ginsenoside pharmacology in the nervous system: involvement in the regulation of ion channels and receptors. Front Physiol 2014; 5: 98
    PubMedGoogle Scholar
  • 14 Nah SY, Kim DH, Rhim H. Ginsenosides: Are any of them candidates for drugs acting on the central nervous system?. CNS Drug Rev 2007; 13: 381-404
    CrossrefPubMedGoogle Scholar
  • 15 Kim JW, Han SW, Cho JY, Chung IJ, Kim JG, Lee KH, Park KU, Baek SK, Oh SC, Lee MA, Oh D, Shim B, Ahn JB, Shin D, Lee JW, Kim YH. Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial. Eur J Cancer 2020; 130: 51-62
    CrossrefPubMedGoogle Scholar
  • 16 Li X, Chu S, Lin M, Gao Y, Liu Y, Yang S, Zhou X, Zhang Y, Hu Y, Wang H, Chen N. Anticancer property of ginsenoside Rh2 from ginseng. Eur J Med Chem 2020; 203: 112627
    CrossrefPubMedGoogle Scholar
  • 17 Zhu H, Liu H, Zhu JH, Wang SY, Zhou SS, Kong M, Mao Q, Long F, Fang ZJ, Li SL. Efficacy of ginseng and its ingredients as adjuvants to chemotherapy in non-small cell lung cancer. Food Funct 2021; 12: 2225-2241
    CrossrefPubMedGoogle Scholar
  • 18 Jiao R, Liu Y, Gao H, Xiao J, So KF. The anti-oxidant and antitumor properties of plant polysaccharides. Am J Chin Med 2016; 44: 463-488
    CrossrefPubMedGoogle Scholar
  • 19 Lee CH, Kim JH. A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. J Ginseng Res 2014; 38: 161-166
    CrossrefPubMedGoogle Scholar
  • 20 Nag SA, Qin JJ, Wang W, Wang MH, Wang H, Zhang R. Ginsenosides as anticancer agents: In vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. Front Pharmacol 2012; 3: 25
    PubMedGoogle Scholar
  • 21 Cho IH. Effects of panax ginseng in neurodegenerative diseases. J Ginseng Res 2012; 36: 342-353
    CrossrefPubMedGoogle Scholar
  • 22 Kim HJ, Kim P, Shin CY. A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. J Ginseng Res 2013; 37: 8-29
    CrossrefPubMedGoogle Scholar
  • 23 Sheng C, Peng W, Xia ZA, Wang Y, Chen Z, Su N, Wang Z. The impact of ginsenosides on cognitive deficits in experimental animal studies of Alzheimerʼs disease: a systematic review. BMC Complement Altern Med 2015; 15: 386
    CrossrefPubMedGoogle Scholar
  • 24 Thal DR, Walter J, Saido TC, Fändrich M. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimerʼs disease. Acta Neuropathol 2015; 129: 167-182
    CrossrefPubMedGoogle Scholar
  • 25 Kam TI, Gwon Y, Jung YK. Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimerʼs disease. Cell Mol Life Sci 2014; 71: 4803-4813
    CrossrefPubMedGoogle Scholar
  • 26 Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimerʼs disease: Pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 2019; 14: 5541-5554
    CrossrefPubMedGoogle Scholar
  • 27 Ma C, Hong F, Yang S. Amyloidosis in Alzheimerʼs disease: Pathogeny, etiology, and related therapeutic directions. Molecules 2022; 27: 1210
    CrossrefPubMedGoogle Scholar
  • 28 Chen W, Balan P, Popovich DG. Analysis of ginsenoside content (Panax ginseng) from different regions. Molecules 2019; 24: 3491
    CrossrefPubMedGoogle Scholar
  • 29 Daina A, Michielin O, Zoete V. SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res 2019; 47: W357-W364
    CrossrefPubMedGoogle Scholar
  • 30 Xu M, Zhang DF, Luo R, Wu Y, Zhou H, Kong LL, Bi R, Yao YG. A systematic integrated analysis of brain expression profiles reveals YAP1 and other prioritized hub genes as important upstream regulators in Alzheimerʼs disease. Alzheimers Dement 2018; 14: 215-229
    CrossrefPubMedGoogle Scholar
  • 31 Zhang T, Yu J, Wang G, Zhang R. Amyloid precursor protein binds with TNFRSF21 to induce neural inflammation in Alzheimerʼs Disease. Eur J Pharm Sci 2021; 157: 105598
    CrossrefPubMedGoogle Scholar
  • 32 Guglielmotto M, Monteleone D, Piras A, Valsecchi V, Tropiano M, Ariano S, Fornaro M, Vercelli A, Puyal J, Arancio O, Tabaton M, Tamagno E. Aβ1–42 monomers or oligomers have different effects on autophagy and apoptosis. Autophagy 2014; 10: 1827-1843
    CrossrefPubMedGoogle Scholar
  • 33 Moussa-Pacha NM, Abdin SM, Omar HA, Alniss H, Al-Tel TH. BACE1 inhibitors: Current status and future directions in treating Alzheimerʼs disease. Med Res Rev 2020; 40: 339-384
    CrossrefPubMedGoogle Scholar
  • 34 Lau SF, Cao H, Fu AKY, Ip NY. Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimerʼs disease. Proc Natl Acad Sci U S A 2020; 117: 25800-25809
    CrossrefPubMedGoogle Scholar
  • 35 Nguyen MD, Mushynski WE, Julien JP. Cycling at the interface between neurodevelopment and neurodegeneration. Cell Death Differ 2002; 9: 1294-1306
    CrossrefPubMedGoogle Scholar
  • 36 Necula D, Riviere-Cazaux C, Shen Y, Zhou M. Insight into the roles of CCR5 in learning and memory in normal and disordered states. Brain Behav Immun 2021; 92: 1-9
    CrossrefPubMedGoogle Scholar
  • 37 Sanchez A, Wadhwani S, Grammas P. Multiple neurotrophic effects of VEGF on cultured neurons. Neuropeptides 2010; 44: 323-331
    CrossrefPubMedGoogle Scholar
  • 38 Ryu JK, Cho T, Choi HB, Wang YT, McLarnon JG. Microglial VEGF receptor response is an integral chemotactic component in Alzheimerʼs disease pathology. J Neurosci 2009; 29: 3-13
    CrossrefPubMedGoogle Scholar
  • 39 Zeng P, Wang XM, Ye CY, Su HF, Tian Q. The main alkaloids in Uncaria Rhynchophylla and their anti-Alzheimerʼs disease mechanism determined by a network pharmacology approach. Int J Mol Sci 2021; 22: 3612
    CrossrefPubMedGoogle Scholar
  • 40 Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019; 47: D607-D613
    CrossrefPubMedGoogle Scholar
  • 41 Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowsk B, Ideker T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504
    CrossrefPubMedGoogle Scholar
  • 42 Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 2019; 10: 1523
    CrossrefPubMedGoogle Scholar
  • 43 Liu Y, Grimm M, Dai WT, Hou MC, Xiao ZX, Cao Y. CB-Dock: a web server for cavity detection-guided protein-ligand blind docking. Acta Pharmacol Sin 2020; 41: 138-144
    CrossrefPubMedGoogle Scholar
  • 44 Wang Q, Jiang H, Wang L, Yi H, Li Z, Liu R. Vitegnoside mitigates neuronal injury, mitochondrial apoptosis, and inflammation in an Alzheimerʼs disease cell model via the p 38 MAPK/JNK pathway. J Alzheimers Dis 2019; 72: 199-214
    CrossrefPubMedGoogle Scholar